An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma

Lee, M. H., Wang, J. H., King, T. M., Chang, M. C., & Hsu, C. W. (2017). Neoadjuvant Concurrent Chemoradiotherapy Might Not be Necessary for Stage III Upper-third Rectal Adenocarcinoma. 中華民國大腸直腸外科醫學會雜誌, 28(1), 11-17. https://doi.org/10.6312/SCRSTW.2017.28(1).10518
謝宜真、盧勝男（2007）。Immediate Complications and Related Factors in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation。實證護理，3(2)，129-138。https://doi.org/10.6225/JEBN.3.2.129
Wiedmann, M. W., & Mössner, J. (2012). Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors. Clinical Medicine Insights: Oncology, (), 381-393. https://doi.org/10.4137/CMO.S7350
Cheng, K. C., Chen, H. H., Chang, C. L., Hu, W. H., Lee, K. C., Tsai, K. L., Lin, Y. M., Huang, E. Y., Hsu, H. C., & Lu, C. C. (2016). Prolonging the Interval between Neoadjuvant Concurrent Chemoradiotherapy and Surgery Improves Pathological Outcomes in Rectal Cancer. 中華民國大腸直腸外科醫學會雜誌, 27(3), 119-126. https://doi.org/10.6312/SCRSTW.2016.27(3).10507
Hsu, C. C., Liu, M. T., Huang, T. H., Lin, C. Y., Huang, C. C., Chang, T. H., & Pi, C. P. (2009). Postoperative Concurrent Chemoradiotherapy for Non-Early Stage Gastric Adenocarcinoma. 放射治療與腫瘤學, 16(1), 25-33. https://doi.org/10.6316/TRO/200916(1)25